A Study of CM350 in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
This is an open label, dose escalation and expansion Phase I/II study to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of
CM350 in patients with advanced solid tumors.
The phase I study consists of a dose escalation part (Part A) and a dose extension part (Part
B).
The safety and tolerability of CM350 and the maximum tolerated dose (MTD) will be evaluated
in Part A.
The safety, tolerability and efficacy of CM350 at MTD and/or the dose of one level less than
MTD (MTD-1), and the recommended dose level for the phase II study will be determined in Part
B.